Literature DB >> 25596289

Renal cell carcinoma with proliferative lupus nephritis.

Koh-Wei Wong1.   

Abstract

We report a case of renal cell carcinoma diagnosed after a patient was treated successfully with intravenous cyclophosphamide for her active proliferative lupus nephritis (classes III and V). After the intravenous cyclophosphamide regimen, the patient was asymptomatic with persistent microscopic haematuria, and no proteinuria. The renal cell carcinoma was located on the left kidney; incidentally, this was where the initial renal biopsy was done to diagnose lupus nephritis. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25596289      PMCID： PMC4307063          DOI： 10.1136/bcr-2014-208060

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  13 in total

1.  Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil.

Authors:  Steven Vernino; Diva R Salomao; Thomas M Habermann; Brian P O'Neill
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

2.  Malignancies and cyclophosphamide exposure in Wegener's granulomatosis.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  J Rheumatol       Date:  2008-01       Impact factor: 4.666

3.  Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil.

Authors:  R Robson; J M Cecka; G Opelz; M Budde; S Sacks
Journal:  Am J Transplant       Date:  2005-12       Impact factor: 8.086

4.  Renal cell carcinoma associated with cyclophosphamide therapy for Wegener's granulomatosis.

Authors:  M Odeh
Journal:  Scand J Rheumatol       Date:  1996       Impact factor: 3.641

Review 5.  Systemic lupus and malignancies.

Authors:  Sasha Bernatsky; Mruganka Kale; Rosalind Ramsey-Goldman; Caroline Gordon; Ann E Clarke
Journal:  Curr Opin Rheumatol       Date:  2012-03       Impact factor: 5.006

6.  Malignancy in systemic lupus erythematosus: what have we learned?

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-08       Impact factor: 4.098

7.  Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

Authors:  L B Travis; R E Curtis; B Glimelius; E J Holowaty; F E Van Leeuwen; C F Lynch; A Hagenbeek; M Stovall; P M Banks; J Adami
Journal:  J Natl Cancer Inst       Date:  1995-04-05       Impact factor: 13.506

8.  Renal cell carcinoma associated immunosuppressive therapy: a case report with Wegener's granulomatosis.

Authors:  Serpil Muge Deger; Ruya Mutluay; Fatma Ayerden Ebinc; Turgay Arinsoy; Sukru Sindel
Journal:  Rheumatol Int       Date:  2009-11       Impact factor: 2.631

9.  Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents.

Authors:  S Vasquez; A F Kavanaugh; N R Schneider; M C Wacholtz; P E Lipsky
Journal:  J Rheumatol       Date:  1992-10       Impact factor: 4.666

10.  Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study.

Authors:  C D Radis; L E Kahl; G L Baker; M C Wasko; J M Cash; A Gallatin; B L Stolzer; A K Agarwal; T A Medsger; C K Kwoh
Journal:  Arthritis Rheum       Date:  1995-08
View more
  1 in total

1.  ZFX is a Strong Predictor of Poor Prognosis in Renal Cell Carcinoma.

Authors:  Changying Li; Hongjie Li; Ting Zhang; Jianmin Li; Fuling Ma; Mei Li; Zhifang Sui; Jiwu Chang
Journal:  Med Sci Monit       Date:  2015-11-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.